Artelo Biosciences Inc. has entered into a definitive agreement with R.F. Lafferty & Co., Inc. to establish an at-the-market equity program. This program allows Artelo to sell up to $6.5 million worth of its common stock through the Manager as needed. The agreement permits sales directly on The Nasdaq Capital Market or other trading platforms, with a commission rate of 2.0% of the gross sales price per share for the Manager. Artelo retains the discretion to set minimum sale prices and can suspend the offering if necessary. The agreement includes standard representations, warranties, and indemnification obligations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.